NASDAQ:COGT Cogent Biosciences (COGT) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free COGT Stock Alerts $7.85 +0.25 (+3.29%) (As of 03:39 PM ET) Add Compare Share Share Today's Range$7.50▼$8.0650-Day Range$5.78▼$7.7652-Week Range$3.67▼$13.50Volume774,936 shsAverage Volume1.94 million shsMarket Capitalization$750.56 millionP/E RatioN/ADividend YieldN/APrice Target$13.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cogent Biosciences alerts: Email Address Cogent Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside75.9% Upside$13.67 Price TargetShort InterestBearish13.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.24Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.89) to ($1.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.01 out of 5 starsMedical Sector648th out of 905 stocksPharmaceutical Preparations Industry298th out of 422 stocks 4.4 Analyst's Opinion Consensus RatingCogent Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCogent Biosciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cogent Biosciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.04% of the outstanding shares of Cogent Biosciences have been sold short.Short Interest Ratio / Days to CoverCogent Biosciences has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Cogent Biosciences has recently increased by 15.04%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCogent Biosciences does not currently pay a dividend.Dividend GrowthCogent Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for COGT. Previous Next 2.4 News and Social Media Coverage News SentimentCogent Biosciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Cogent Biosciences this week, compared to 2 articles on an average week.Search Interest3 people have searched for COGT on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Cogent Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cogent Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.92% of the stock of Cogent Biosciences is held by insiders.Read more about Cogent Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cogent Biosciences are expected to grow in the coming year, from ($1.89) to ($1.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cogent Biosciences is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cogent Biosciences is -3.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCogent Biosciences has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cogent Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Cogent Biosciences Stock (NASDAQ:COGT)Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More COGT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart COGT Stock News HeadlinesMay 9, 2024 | americanbankingnews.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 8, 2024 | markets.businessinsider.comBuy Rating on Cogent Biosciences Backed by Strong Financials and Promising Drug TrialsMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clover Health Investments (CLOV), Cogent Biosciences (COGT) and Adaptive Biotechnologies (ADPT)May 7, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Based on Promising Clinical Trials and Market PositionMay 7, 2024 | finance.yahoo.comCogent Biosciences Reports First Quarter 2024 Financial ResultsApril 18, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cogent Biosciences, Inc. (NASDAQ: COGT)April 9, 2024 | globenewswire.comCogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 InhibitorMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.March 16, 2024 | finance.yahoo.comCOGT Apr 2024 7.500 callMarch 14, 2024 | insidermonkey.com5 Best Biotech Stocks To Buy Under $20February 28, 2024 | finance.yahoo.comCOGT Reports Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | msn.comBaird Downgrades Cogent Biosciences (COGT)February 26, 2024 | msn.comCogent Biosciences GAAP EPS of -$0.63February 26, 2024 | globenewswire.comCogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsFebruary 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cogent Biosciences as Bezuclastinib Showcases Strong Market PotentialFebruary 23, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Lantheus (LNTH) and Ardelyx (ARDX)February 22, 2024 | msn.comCogent Biosciences stock jumps on Phase 2 data for bezuclastinibFebruary 22, 2024 | globenewswire.comCogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisFebruary 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cogent Biosciences Amid Positive Outlook for Bezuclastinib’s Efficacy and SafetyFebruary 15, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Bolsters Position in Cogent BiosciencesFebruary 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Elevance Health (ELV) and Cogent Biosciences (COGT)February 14, 2024 | seekingalpha.comCogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data CatalystFebruary 14, 2024 | finance.yahoo.comCogent Biosciences Announces Oversubscribed $225 Million Private PlacementFebruary 14, 2024 | globenewswire.comCogent Biosciences Announces Oversubscribed $225 Million Private PlacementFebruary 5, 2024 | finance.yahoo.comCogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual MeetingJanuary 9, 2024 | msn.comCogent Biosciences issues study updates on bezuclastinib, CGT4859See More Headlines Receive COGT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today5/09/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:COGT CUSIPN/A CIK1460329 Webwww.cogint.com Phone(617) 945-5576FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$20.00 Low Stock Price Target$8.00 Potential Upside/Downside+75.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-192,410,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-86.67% Return on Assets-58.11% Debt Debt-to-Equity RatioN/A Current Ratio7.09 Quick Ratio7.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book3.38Miscellaneous Outstanding Shares95,613,000Free Float89,953,000Market Cap$742.91 million OptionableOptionable Beta1.57 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Andrew R. Robbins M.B.A. (Age 48)President, CEO & Director Comp: $1.06MDr. John Edward Robinson Ph.D. (Age 49)Chief Scientific Officer Comp: $749.89kDr. Jessica Sachs M.D. (Age 49)Chief Medical Officer Comp: $773.92kMr. John L. Green C.A. (Age 44)CPA, CFO & Principal Accounting Officer Comp: $763.99kMr. Brad BarnettChief Technology OfficerChristi WaarichSenior Director of Investor RelationsMr. Evan D. Kearns J.D. (Age 44)Chief Legal Officer & Corporate Secretary Ms. Erin SchellhammerChief People OfficerMr. Dana R. Martin Pharm.D.Senior Vice President of Medical AffairsBrad FellSenior Vice President of ChemistryMore ExecutivesKey CompetitorsArcturus TherapeuticsNASDAQ:ARCTPureTech HealthNASDAQ:PRTCSIGA TechnologiesNASDAQ:SIGAAurinia PharmaceuticalsNASDAQ:AUPHY-mAbs TherapeuticsNASDAQ:YMABView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 8,160 shares on 5/9/2024Ownership: 0.016%Entropy Technologies LPBought 31,632 shares on 5/8/2024Ownership: 0.033%ProShare Advisors LLCBought 2,953 shares on 5/8/2024Ownership: 0.023%Russell Investments Group Ltd.Bought 7,020 shares on 5/8/2024Ownership: 0.010%49 Wealth Management LLCBought 2,236 shares on 5/7/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions COGT Stock Analysis - Frequently Asked Questions Should I buy or sell Cogent Biosciences stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cogent Biosciences in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COGT shares. View COGT analyst ratings or view top-rated stocks. What is Cogent Biosciences' stock price target for 2024? 7 Wall Street analysts have issued 12-month price objectives for Cogent Biosciences' shares. Their COGT share price targets range from $8.00 to $20.00. On average, they predict the company's stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 75.9% from the stock's current price. View analysts price targets for COGT or view top-rated stocks among Wall Street analysts. How have COGT shares performed in 2024? Cogent Biosciences' stock was trading at $5.88 at the beginning of the year. Since then, COGT stock has increased by 32.1% and is now trading at $7.77. View the best growth stocks for 2024 here. Are investors shorting Cogent Biosciences? Cogent Biosciences saw a increase in short interest in April. As of April 15th, there was short interest totaling 12,470,000 shares, an increase of 15.0% from the March 31st total of 10,840,000 shares. Based on an average daily volume of 2,100,000 shares, the days-to-cover ratio is currently 5.9 days. View Cogent Biosciences' Short Interest. When is Cogent Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our COGT earnings forecast. How were Cogent Biosciences' earnings last quarter? Cogent Biosciences, Inc. (NASDAQ:COGT) announced its earnings results on Tuesday, May, 7th. The technology company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.11. What ETFs hold Cogent Biosciences' stock? ETFs with the largest weight of Cogent Biosciences (NASDAQ:COGT) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).Tema Oncology ETF (CANC). What other stocks do shareholders of Cogent Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Viveve Medical (VIVE), Red Violet (RDVT), Freeport-McMoRan (FCX), HP (HPQ), Nutanix (NTNX), OPKO Health (OPK), STMicroelectronics (STM) and Actinium Pharmaceuticals (ATNM). Who are Cogent Biosciences' major shareholders? Cogent Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Swiss National Bank (0.13%), Mirae Asset Global Investments Co. Ltd. (0.05%), Entropy Technologies LP (0.03%), ProShare Advisors LLC (0.02%), China Universal Asset Management Co. Ltd. (0.02%) and State Board of Administration of Florida Retirement System (0.02%). View institutional ownership trends. How do I buy shares of Cogent Biosciences? Shares of COGT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:COGT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersThis 1 Biotech Stock has been shocking the marketsHuge Alerts1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDems have chosen Biden replacement?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.